BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-711 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-711\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07241039-2321@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ABBV-711: Phase 1 readout est. (NCT07241039)
DESCRIPTION:ABBV-711\, phase 1.\nStudy: A Study to Assess the Adverse Event
 s\, Change in Disease Activity\, and How Oral ABBV-711 Tablets Move Throug
 h the Body as a Monotherapy and in Combination With Intravenously Infused 
 Budigalimab (ABBV-181)\, in Adults With Advanced Squamous Tumors\nEstimate
 d primary completion: April 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/abbv-711#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07241039
URL:https://assetmemo.bio/drug/abbv-711#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
